Evidence map›Paper›PMID 36287279›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2022

Overestimation of the effect of (fos)aprepitant on intravenous dexamethasone pharmacokinetics requires adaptation of the guidelines for children with chemotherapy-induced nausea and vomiting.

A Laura Nijstad, Evelien de Vos-Kerkhof, Catherine F Enters-Weijnen, Marianne D van de Wetering, Wim J E Tissing, Matthijs M Tibben, Hilde Rosing, Arief Lalmohamed, Alwin D R Huitema, C Michel Zwaan

Open access · hybridAbstract read
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Evaluation of chemotherapy-induced nausea and vomiting in pediatric patients with high-grade glioma treated with lomustine-a case series.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

A Laura Nijstad *Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0003-3448-7665
Evelien de Vos-Kerkhof *Princess Máxima Center for Pediatric Oncology, Postbus 113, 3720 AC, Bilthoven, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-4828-7069
Catherine F Enters-WeijnenPrincess Máxima Center for Pediatric Oncology, Postbus 113, 3720 AC, Bilthoven, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0003-1412-0938
Marianne D van de WeteringPrincess Máxima Center for Pediatric Oncology, Postbus 113, 3720 AC, Bilthoven, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0003-4127-3032
Wim J E TissingPrincess Máxima Center for Pediatric Oncology, Postbus 113, 3720 AC, Bilthoven, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0001-9101-507X
Matthijs M TibbenDepartment of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Hilde RosingDepartment of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0003-3124-692X
Arief LalmohamedDepartment of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-3149-3501
Alwin D R Huitema *Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0003-1939-4639
C Michel Zwaan *Princess Máxima Center for Pediatric Oncology, Postbus 113, 3720 AC, Bilthoven, Utrecht, The Netherlands. c.m.zwaan@prinsesmaximacentrum.nl.ORCID http://orcid.org/0000-0001-6892-8268
Princess Máxima Center · NLThe Netherlands Cancer Institute · NLUniversity Medical Center Utrecht · NLUniversity Medical Center Groningen · NLUtrecht University · NL

Funding

Stichting Kinderen Kankervrij 320
6 · The paper itself

Abstract

purposeChemotherapy-induced nausea and vomiting (CINV) are common side effects in pediatric oncology treatment. Besides 5-HT

methodsIn total, 65 children (0.6-17.9 years), receiving intravenous or oral antiemetic therapy (dexamethasone ± aprepitant) as standard of care, were included. 305 dexamethasone plasma concentrations were determined using LC-MS/MS. An integrated dexamethasone and aprepitant pharmacokinetic model was developed using non-linear mixed effects modelling in order to investigate the effect of aprepitant administration on dexamethasone CL.

resultsIn this population, dexamethasone CL in patients with concomitant administration of aprepitant was reduced by approximately 30% of the uninhibited CL (23.3 L/h (95% confidence interval 20.4-26.0)). This result is not consistent with the results of adult studies (50% reduction). This difference was not age dependent, but might be related to the route of administration of dexamethasone. Future studies are needed to assess the difference in oral/intravenous dexamethasone.

conclusionWhen dexamethasone is given intravenously as a component of triple therapy to prevent CINV in children, we advise to reduce the dexamethasone dose by 30% instead of 50%.

Indexed as

AntiemeticsAntineoplastic AgentsAdultAprepitantChildChromatography, LiquidDexamethasoneDrug Therapy, CombinationHumansMorpholinesNauseaTandem Mass SpectrometryVomitingAntiemeticsAntineoplastic AgentsAprepitantDexamethasoneMorpholinesAntiemeticsChildhood cancerOncologyPediatricsPharmacokinetics

Identifiers

PMID36287279
PMCPMC9607815
OpenAlexW4307573436

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.